The Latest Breaking News from Vaccine

The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ (NYSE: EBS) Biologics License Application (BLA) for its new anthrax vaccine candidate AV7909. The regulatory agency sets the Prescription Drug User Fee Act (PDUFA) goal date for a decision in month of April 2023.

Around 66 per cent of the global has received at least one dose of a Covid vaccine.

First major analysis examines impact across 185 countries since first jab was administered in December 2020

Reuters

London health authorities are investigating a likely outbreak of polio, the first in nearly 40 years. One in 200 infections causes irreversible paralysis.

When the Centers for Disease Control and Prevention endorsed both the Pfizer-BioNTech and Moderna COVID-19 vaccines for all children ages 6 months to 5 years on June 18, 2022, it opened the door for nearly 20 million children to get vaccinated.

Moderna, Inc. (NASDAQ: MRNA) rose to prominence with its messenger RNA-based COVID-19 vaccine.

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate.  "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Recent reports of poliovirus detected in samples from a sewage treatment works in London have rightly generated significant concern among public health agencies and medical staff. The poliovirus detected is what is called vaccine-derived poliovirus – this is not “wild poliovirus”.